# Efficacy of Reinforcing Standard Therapy in COVID-19 Patients With Repeated Transfusion of Convalescent Plasma

> **NCT04803370** · NA · COMPLETED · sponsor: **Hospital Son Llatzer** · enrollment: 55 (actual)

## Conditions studied

- Covid19

## Interventions

- **OTHER:** Convalescent Plasma with antibody against SARS-CoV-2.
- **OTHER:** Standard treatment for COVID-19

## Key facts

- **NCT ID:** NCT04803370
- **Lead sponsor:** Hospital Son Llatzer
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-07-08
- **Primary completion:** 2021-09-01
- **Final completion:** 2021-09-01
- **Target enrollment:** 55 (ACTUAL)
- **Last updated:** 2025-09-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04803370

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04803370, "Efficacy of Reinforcing Standard Therapy in COVID-19 Patients With Repeated Transfusion of Convalescent Plasma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04803370. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*